Home

aptamersnucleic

Aptamers are short single-stranded DNA or RNA molecules that fold into defined three-dimensional structures, enabling high-affinity and high-specificity binding to a wide range of targets, from small molecules to proteins, cells, and whole organisms. They are generated from large libraries of randomized sequences through in vitro selection methods, most commonly SELEX (systematic evolution of ligands by exponential enrichment). In SELEX, successive rounds of binding, separation of bound from unbound sequences, and amplification enrich aptamers with the desired binding properties. Variants include cell-SELEX, which selects against cell-surface targets, and capillary electrophoresis SELEX, which can increase selection stringency and speed. RNA aptamers can be reverse-transcribed to DNA for amplification, while DNA aptamers are typically more chemically stable.

Chemistry and optimization: Aptamers may be composed of DNA or RNA and are often endowed with chemically

Applications: In medicine, aptamers have been explored as therapeutics, including anti-VEGF agents such as pegylated Macugen

Advantages and limitations: Aptamers offer synthetic production, low immunogenicity, and easy modification, with the potential for

modified
nucleotides
to
enhance
nuclease
resistance,
affinity,
or
pharmacokinetic
properties.
After
selection,
truncation
and
structure-guided
design
can
improve
performance.
Aptamers
are
frequently
conjugated
to
fluorophores,
biotin,
nanoparticles,
or
therapeutic
cargos
to
enable
detection,
imaging,
or
targeted
delivery.
L-nucleotide
Spiegelmers
provide
nuclease
resistance
and
distinct
binding
characteristics.
for
neovascular
age-related
macular
degeneration.
In
diagnostics,
aptamer-based
assays
and
biosensors
enable
rapid
detection
of
various
analytes.
In
research
and
industry,
aptamers
serve
as
affinity
reagents,
imaging
probes,
and
components
of
targeted
delivery
systems.
precise
pharmacokinetic
tuning.
Limitations
include
susceptibility
to
nucleases
(addressed
by
chemical
modifications),
potential
off-target
effects,
and
clearance
challenges
for
small
aptamers.
Regulatory
and
development
progress
continues,
with
ongoing
advances
in
selection
technologies
and
applications.